NEULAND LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,255 INR | +0.51% |
|
-12.33% | +18.30% |
| May. 14 | Transcript : Neuland Laboratories Limited, Q4 2024 Earnings Call, May 14, 2024 | |
| May. 10 | Neuland Laboratories' Consolidated Profit Declines in Fiscal Q4 | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,652 | 3,637 | 26,788 | 13,171 | 23,087 | 80,249 | - | - |
| Enterprise Value (EV) 1 | 8,652 | 3,637 | 26,788 | 13,171 | 23,087 | 80,588 | 76,681 | 74,586 |
| P/E ratio | 51.6 x | 22.4 x | 33.2 x | 20.6 x | 14.1 x | 26.9 x | 26.7 x | 21.3 x |
| Yield | 0.18% | 0.71% | 0.24% | - | 0.56% | 0.19% | 0.15% | 0.23% |
| Capitalization / Revenue | 1.3 x | 0.48 x | 2.86 x | 1.38 x | 1.94 x | 5.17 x | 5.02 x | 4.19 x |
| EV / Revenue | 1.3 x | 0.48 x | 2.86 x | 1.38 x | 1.94 x | 5.17 x | 4.8 x | 3.9 x |
| EV / EBITDA | 14.8 x | 3.57 x | 18.2 x | 9.24 x | 8.49 x | 17.4 x | 18 x | 13 x |
| EV / FCF | 127 x | 42.6 x | 31.9 x | -35.3 x | 13.5 x | 32.2 x | 26.1 x | 24.1 x |
| FCF Yield | 0.79% | 2.35% | 3.13% | -2.83% | 7.41% | 3.1% | 3.83% | 4.15% |
| Price to Book | - | 0.52 x | 3.42 x | 1.58 x | - | 6.21 x | 5.11 x | 4.14 x |
| Nbr of stocks (in thousands) | 12,830 | 12,830 | 12,830 | 12,830 | 12,830 | 12,830 | - | - |
| Reference price 2 | 674.4 | 283.4 | 2,088 | 1,027 | 1,799 | 6,255 | 6,255 | 6,255 |
| Announcement Date | 5/16/19 | 5/22/20 | 5/11/21 | 5/10/22 | 5/11/23 | 5/10/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,668 | 7,627 | 9,369 | 9,511 | 11,912 | 15,586 | 15,980 | 19,132 |
| EBITDA 1 | 583.7 | 1,019 | 1,468 | 1,426 | 2,718 | 4,626 | 4,272 | 5,748 |
| EBIT 1 | - | 706.1 | 1,071 | 935.8 | - | 4,029 | 3,856 | 5,260 |
| Operating Margin | - | 9.26% | 11.44% | 9.84% | - | 25.85% | 24.13% | 27.49% |
| Earnings before Tax (EBT) 1 | 203.4 | 529.2 | 1,053 | 821.6 | 2,157 | 4,014 | 4,023 | 5,061 |
| Net income 1 | 164.4 | 162.1 | 806.3 | 638.2 | 1,635 | 3,001 | 3,017 | 3,796 |
| Net margin | 2.47% | 2.13% | 8.61% | 6.71% | 13.73% | 19.25% | 18.88% | 19.84% |
| EPS 2 | 13.06 | 12.63 | 62.85 | 49.74 | 127.4 | 233.9 | 233.9 | 294.2 |
| Free Cash Flow 1 | 67.95 | 85.44 | 839.6 | -373 | 1,711 | 2,418 | 2,938 | 3,095 |
| FCF margin | 1.02% | 1.12% | 8.96% | -3.92% | 14.36% | 15.28% | 18.39% | 16.18% |
| FCF Conversion (EBITDA) | 11.64% | 8.39% | 57.19% | - | 62.93% | 50.77% | 68.78% | 53.84% |
| FCF Conversion (Net income) | 41.33% | 52.71% | 104.13% | - | 104.63% | 77.8% | 97.38% | 81.53% |
| Dividend per Share 2 | 1.200 | 2.000 | 5.000 | - | 10.00 | 12.18 | 9.500 | 14.55 |
| Announcement Date | 5/16/19 | 5/22/20 | 5/11/21 | 5/10/22 | 5/11/23 | 5/10/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,454 | 2,447 | 2,009 | 2,559 | 2,212 | 2,937 | 4,071 | 3,630 | 3,466 | 3,635 | 4,068 | 3,778 |
| EBITDA 1 | 466 | 255.1 | 256.9 | 388.7 | 286 | 693 | 1,199 | 969.2 | 884 | 1,040 | 1,175 | - |
| EBIT | - | - | - | - | - | - | - | - | - | - | 1,026 | 821.6 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | 25.22% | 21.75% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 267.4 | 172.9 | 87.34 | 217.8 | 99.66 | 384.6 | 845.4 | 618.8 | 548 | 658 | 744 | - |
| Net margin | 10.89% | 7.07% | 4.35% | 8.51% | 4.51% | 13.09% | 20.77% | 17.05% | 15.81% | 18.1% | 18.29% | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/2/21 | 5/11/21 | 8/3/21 | 5/10/22 | 8/3/22 | 11/10/22 | 5/11/23 | 8/3/23 | - | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 2,325 | 3,568 | 5,663 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 68 | 85.4 | 840 | -373 | 1,711 | 2,418 | 2,938 | 3,095 |
| ROE (net income / shareholders' equity) | 2.62% | 2.3% | 10.8% | 7.85% | 17.8% | 27.1% | 21.1% | 21.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 550.0 | 610.0 | 652.0 | - | 1,007 | 1,223 | 1,512 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 631 | 488 | 1,054 | 959 | 661 | 899 | 378 | 800 |
| Capex / Sales | 9.46% | 6.4% | 11.25% | 10.08% | 5.55% | 5.68% | 2.37% | 4.18% |
| Announcement Date | 5/16/19 | 5/22/20 | 5/11/21 | 5/10/22 | 5/11/23 | 5/10/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6,255
INR
Average target price
8,300
INR
Spread / Average Target
+32.70%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.30% | 956M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- NEULANDLAB Stock
- Financials Neuland Laboratories Limited
